Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Ph2a study that consists of a double-blind, intra-patient placebo-controlled treatment period and an open-label uncontrolled treatment period with objective to evaluate the safety, tolerability, PK and preliminary efficacy of PRN473 in up to 40 patients with mild to moderate AD.

On Day 1 (Baseline) of the Blinded Period, 2 target lesions with a difference no greater than 1 point in Total Sign Score (TSS) will be randomly assigned to treatment in an intra-patient 1:1 manner, one lesion to PRN473 and the other to matching placebo.

Participation will take approximately 13 weeks, including up to a 5-week screening period, a 6-week treatment period, end of study assessments 1 day after last dose, and a safety follow-up phone call 2 weeks after last dose.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Principia Biopharma, a Sanofi Company

Criteria

Inclusion Criteria:

• Male and female adults 18 to 70 years of age (inclusive) at the time of informed consent.

• Diagnosed with mild to moderate AD.

• History of AD for at least 6 months as determined by the Investigator through patient interview.

• Stable disease for the 4 weeks prior to the screening visit with no significant flares in AD as determined by the Investigator.

• Validated Investigator Global Assessment-atopic dermatitis (vIGA-AD) score of Moderate or Mild at Screening. The vIGA-AD is evaluated for the entire body except scalp, palms, soles and genitals.

• Has AD involvement (excluding scalp, palms, soles and genitals) of at least 1.0% BSA and no more than 14.0% BSA.

• Has at least two target lesions 100 cm2 or greater with a difference no greater than 1 point in lesion TSS and at least 5 cm apart located on the trunk (excluding genitals) or upper extremities (excluding palms).

• If female, patients with child-bearing potential must have a negative pregnancy test, and agree to practice true abstinence or agree to use highly effective contraception.

• If male, agree to use a male condom and highly effective contraception with female partners of child-bearing potential.

• In good health as judged by the Investigator.

Exclusion Criteria:

• Patients who have failed 2 or more prior systemic treatments for AD.

• Patients who have received a live or attenuated vaccine in the last 12 weeks or intend to receive a live or attenuated vaccine during the study.

• Patients who cannot discontinue prohibited medications and treatments prior to the Baseline visit and during the study.

• Has unstable AD, based on the judgement of the Investigator, or any consistent requirement for high potency topical steroids to manage AD signs or symptoms.

• Patients who have significant active systemic or localized bacterial, viral, fungal, and helminth infection in the last 30 days.

• Patients unwilling to refrain from prolonged sun exposure or use of a tanning bed or other artificial light emitting devices for 4 weeks prior to Baseline and during the study.

• Patients with other skin conditions that would interfere with evaluations of the effect of the study medication on AD, as determined by the Investigator.

• Patients with known genetic dermatological conditions that overlap with AD, such as Netherton syndrome.

• Previous use of a BTK inhibitor.

• Women who are pregnant, wishing to become pregnant during the study, or are breastfeeding.

• Patients currently undergoing allergy (eg, food allergy testing or skin prick testing), patch testing, or food challenges, or plan to do so during the study.

• Patients who have undergone major surgery within 4 weeks prior to Day 1 or patients who have a major surgery planned during the study.

• Regular use of drugs of abuse or regular alcohol consumption within 6 months prior to the study.